Bleomycin for Injection — Class I drug recall D-0261-2024
Ongoing recall by PFIZER, reported 2024-01-31, distributed nationwide. Presence of particulate matter: glass
| Recall number | D-0261-2024 |
|---|---|
| Product type | Drug |
| Classification | Class I |
| Status | Ongoing |
| Voluntary or mandated | Voluntary |
| Recalling firm | PFIZER, New York, NY, United States |
| Recall initiated | 2023-12-21 |
| Classified | 2024-01-25 |
| Reported by FDA | 2024-01-31 |
| Distributed | Nationwide (US) |
| Countries outside the US | NL |
| Quantity | 3,546 vials |
| Reason classes | foreign material, specification failure |
| NDC | 61703-0323, 61703-0323-22, 61703-0332, 61703-0332-18 |
| Lot numbers | BL12206A |
| Expiration dates | 2024-06-30 |
Product
Bleomycin for Injection, USP, 15 units per vial, 1 single dose glass fliptop vial, Rx Only, Distributed by: Hospira, Inc., Lake Forest, IL 68045, NDC 61703-332-18
Reason for recall
Presence of particulate matter: glass
Machine access
This record, with every extracted code, the verbatim FDA record and provenance, is available from the recall API: GET https://api.data.aroqon.com/v1/recalls/D-0261-2024. Look up any UPC, UDI, NDC or lot with /v1/recalls/lookup?code=…. API docs · free and paid keys.
Source: U.S. Food and Drug Administration enforcement report via openFDA (CC0). Structured by Data Foundry (recall-structuring@2); last changed 2026-09-26. Not affiliated with or endorsed by FDA. Not medical or legal advice.